Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics INC (KPTI)
:KPTI
KPTI Analyst Ratings
Moderate Buy
3 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
KPTI Stock 12 Month Forecast
Average Price Target
$15.80
▲(162.46% Upside)
| Highest Price Target$30.00 | Average Price Target$15.80 | Lowest Price Target$6.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$4→$6
Hold
-0.33%
Downside
Reiterated
08/16/25
Robert W. Baird
$42→$25
Buy
315.28%
Upside
Reiterated
08/12/25
Barclays
$10
Buy
66.11%
Upside
Reiterated
08/12/25
Leerink Partners
$8
Hold
32.89%
Upside
Reiterated
08/12/25
Cautious Hold on Karyopharm Therapeutics Amid Revenue Guidance Cut and Clinical DelaysWe remain on the sidelines awaiting more durable growth trends on Xpovio sales, convincing evidence that Xpovio sales growth will not be overshadowed by existing operating expenses, and a clearer picture on the potential opportunities for Xpovio beyond multiple myeloma. Reiterate MP.
RBC Capital
$30
Buy
398.34%
Upside
Reiterated
08/11/25
H.C. Wainwright
―
Hold
―
Downgraded
07/16/25
Piper Sandler
$75→$15
Buy
149.17%
Upside
Reiterated
03/19/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$4→$6
Hold
-0.33%
Downside
Reiterated
08/16/25
Robert W. Baird
$42→$25
Buy
315.28%
Upside
Reiterated
08/12/25
Barclays
$10
Buy
66.11%
Upside
Reiterated
08/12/25
Leerink Partners
$8
Hold
32.89%
Upside
Reiterated
08/12/25
Cautious Hold on Karyopharm Therapeutics Amid Revenue Guidance Cut and Clinical DelaysWe remain on the sidelines awaiting more durable growth trends on Xpovio sales, convincing evidence that Xpovio sales growth will not be overshadowed by existing operating expenses, and a clearer picture on the potential opportunities for Xpovio beyond multiple myeloma. Reiterate MP.
RBC Capital
$30
Buy
398.34%
Upside
Reiterated
08/11/25
H.C. Wainwright
―
Hold
―
Downgraded
07/16/25
Piper Sandler
$75→$15
Buy
149.17%
Upside
Reiterated
03/19/25
Best Analysts Covering Karyopharm Therapeutics
1 Month
xxx
Success Rate
11/34 ratings generated profit
Average Return
-4.18%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 32.35% of your transactions generating a profit, with an average return of -4.18% per trade.
3 Months
xxx
Success Rate
12/34 ratings generated profit
Average Return
-12.95%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 35.29% of your transactions generating a profit, with an average return of -12.95% per trade.
1 Year
Success Rate
5/34 ratings generated profit
Average Return
-38.34%
reiterated a buy rating 12 days ago
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 14.71% of your transactions generating a profit, with an average return of -38.34% per trade.
2 Years
xxx
Success Rate
4/34 ratings generated profit
Average Return
-45.59%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 11.76% of your transactions generating a profit, with an average return of -45.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KPTI Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
8
6
4
5
5
Buy
0
0
0
0
0
Hold
2
4
3
11
12
Sell
8
6
4
2
1
Strong Sell
0
0
0
0
0
total
18
16
11
18
18
Each month's total comprises the sum of three months' worth of ratings.
KPTI Financial Forecast
KPTI Stock Forecast FAQ
What is KPTI’s average 12-month price target, according to analysts?
Based on analyst ratings, Karyopharm Therapeutics INC’s 12-month average price target is 15.80.
What is KPTI’s upside potential, based on the analysts’ average price target?
Karyopharm Therapeutics INC has 162.46% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KPTI a Buy, Sell or Hold?
Karyopharm Therapeutics INC has a consensus rating of Moderate Buy which is based on 3 buy ratings, 3 hold ratings and 0 sell ratings.
What is Karyopharm Therapeutics INC’s price target?
The average price target for Karyopharm Therapeutics INC is 15.80. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $6.00. The average price target represents 162.46% Increase from the current price of $6.02.
The highest analyst price target is $30.00 ,the lowest forecast is $6.00. The average price target represents 162.46% Increase from the current price of $6.02.
What do analysts say about Karyopharm Therapeutics INC?
Karyopharm Therapeutics INC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of KPTI?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.